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Data from the Pharmacogenomics and Risk of Cardiovascular Disease (PARC) study and the Cardiovascular Health Study (CHS) provide
independent and conﬁrmatory evidence for association between common polymorphisms of the HNF1A gene encoding hepatocyte
nuclear factor-1a and plasma C-reactive protein (CRP) concentration. Analyses with the use of imputation-based methods to combine
genotype data from both studies and to test untyped SNPs from the HapMap database identiﬁed several SNPs within a 5 kb region
of HNF1A intron 1 with the strongest evidence of association with CRP phenotype.High basal levels of C-reactive protein predict future cardio-
vascular disease and metabolic abnormalities in otherwise
healthy adults. Several CRP gene (MIM 123260) polymor-
phisms are associated with plasma CRP concentration,1
but these account for only a small proportion of the
30%–50% reported heritability2,3 Whether polymor-
phisms within other regulatory genes account for interin-
dividual variation in plasmaCRP levels is largely unknown.
We report the results of two genetic-association studies of
CRP, the Pharmacogenomics and Risk of Cardiovascular
Disease (PARC) study and the Cardiovascular Health Study
(CHS). In both studies, procedures were conducted under
institutionally approved protocols for work with human
subjects.
The PARC study is a two-stage genome-wide association
(GWA) study. In stage 1, 980 subjects were typed for
317,000 tagSNPs with the Illumina Human-1 BeadChip.
In stage 2, 930 additional subjects were typed for a subset
of 13,680 SNPs with the Illumina iSelect platform, as de-
scribed in the Appendix. The PARC study participants
were derived from two component studies, the Cholesterol
and Atherosclerosis Pharmacogenetics (CAP)4 and the Pra-
vastatin Inﬂammation/CRP Evaluation (PRINCE)5 studies.
All subjects were of self-reported European ancestry. In
both studies, CRP levels were determined with a clinically
validated high-sensitivity assay.6 The current analyses are
based on the combination of serial plasma CRP obtained
at baseline and that obtained after 12 weeks of pravastatin
treatment in PRINCE and at screening, after a two-week
placebo run-in, and following four and six weeks of sim-
vastatin treatment in CAP (see Appendix). CRP phenotypeThe Aminformation is available for a total of 909 subjects in stage 1
and 773 in stage 2. Descriptive characteristics of the PARC
study participants are summarized in Table 1.
We tested each SNP for association with plasma CRP
concentration by computing single-SNP log10(Bayes Fac-
tors or BFs) to quantify the strength of evidence for associ-
ation.7 Bayes Factors have several advantages over p values
in their assessment of evidence of an association.7,8 In
particular, BF calculations take account of power, so that,
unlike p values, proper interpretation of a BF does not de-
pend on the size of the study, SNP minor-allele frequency,
or other factors affecting power. To interpret a BF, the rela-
tionship ‘‘Posterior Odds ¼ Prior Odds3 BF’’ is helpful. For
example, if 1 in 10,000 SNPs are genuinely associated with
CRP (Prior Odds ¼ 1:10,001), then a single-SNP log10(BF)
of 5, 4, or 3 will result, respectively, in Posterior Odds of
approximately 10:1, 1:1 and 1:10, which correspond to
a 91%, 50%, and 9% chance of being a genuine associa-
tion. (Naturally, different prior odds yield different proba-
bilities of a genuine association, and the reader is free to
substitute alternative prior odds. Note that the proportion
of associations with a given p value that are genuine will
also depend on the prior odds, but not in an easily speciﬁed
way.)
The top nine SNPs [log10(BF) > þ3] associated with
plasma CRP concentration in the combined PARC phase
1 þ phase 2 analysis are shown in Table 2. These include
four SNPs located within ~50 kb of the CRP gene on chro-
mosome 1 and one SNP located on chromosome 19 in
the 50 ﬂanking region of the APOE gene (MIM 107741).
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chromosome 12 in the region of the HNF1A gene (also
known as TCF1 [MIM 142410]), which encodes the tran-
scription factor hepatocyte nuclear factor (HNF)-1a. Analy-
ses that controlled for potential within-Europe population
structure with the use of principal-components analysis9
produced only slightly reduced Bayes Factors for these
SNPs (data not shown), suggesting that these are not spuri-
ous associations due to population stratiﬁcation. Further,
the overall distribution of log10(BF) agreed well with its
expectation under the null (Figure 1), suggesting that our
results are not greatly affected by other potential sources
of systematic bias.
Although the log10(BF) of 3.5 for the most strongly
associated SNP in HNF1A (rs7953249) represents only
modest evidence for association with CRP, independent
conﬁrmation of this ﬁnding was provided through a candi-
date-gene-based association analysis of 4333 European-
descended participants 65 years and older from the Cardio-
vascular Health Study (CHS).10 Descriptive characteristics
of the CHS participants are summarized in Table 1. In the
CHS, 979 tagSNPs were typed across 132 candidate genes
chosen on the basis of involvement in inﬂammation,
aging, innate immunity, blood coagulation, and/or regula-
tion of the acute-phase response, as described previously.11
Measurement of plasma CRP was performed at two time
points: at study entry and during a follow-up examination
Table 1. PARC and CHS Participant Baseline Characteristics
Characteristic PARC stage 1 PARC stage 2 CHS
Number 909 773 4,333
Mean age (years) 625 14 63 5 13 735 6
Female sex (%) 32 25 57
Current smokers (%) 14 14 11
Hormone replacement
therapy use (%)
3 1 6
Body mass index (kg/m2) 28.65 5.3 28.8 5 5.3 26.45 4.5
Total cholesterol (mg/dl) 2155 37 2155 39 2125 39
LDL cholesterol (mg/dl) 1325 28 1335 31 1305 36
HDL cholesterol (mg/dl) 425 14 40 5 13 545 16
Triglycerides (mg/dl) 1825 122 1865 125 1445 79
CRP level (mg/l) 0.895 1.52 0.69 5 1.27 3.45 5.9
Data are presented as number (%) or mean 5 standard deviation, unless
otherwise indicated.1194 The American Journal of Human Genetics 82, 1193–1201, Mathat occurred three years after the baseline examination,
with the use of a high-sensitivity enzyme-linked immuno-
sorbent assay12 and an immunonephelometry (BN-II in-
strument, Dade-Behring, Deerﬁeld, Ill), respectively. Both
the enzyme-linked immunosorbent assay and the nephe-
lometric assays were standardized according to the World
Health Organization reference plasma and yield highly
correlated values.
For the candidate-gene study in the CHS, we performed
the analysis in two stages. For each gene, a ‘‘global’’ BF
and a p value test of the null hypothesis of no association
between any SNP in the candidate region were computed.
If there was non-negligible evidence against the global
null hypothesis for a particular candidate gene, we then
computed single-SNP-speciﬁc BF and p values to summa-
rize the evidence for which variants in the region are asso-
ciated with plasma CRP levels. The CRP gene [log10(global
BF) ¼ þ24.8], the APOE gene [log10(global BF) ¼ þ9.9]
and the HNF1A gene [log10(global BF) ¼ þ7.7] showed
the strongest evidence of association with CRP phenotype
in the CHS (Table 3). Several other candidate genes
had much weaker evidence for association with CRP
(Table 3).
Given that associations between the CRP gene1 or
the APOE gene13,14 and CRP have been reported previ-
ously, we focused the current analysis on further character-
ization of the newly described association between the
HNF1A genotype and the CRP phenotype. Five of the eight
HNF1A SNPs typed in the CHS showed evidence of associ-
ation (log10BF > þ3.0 or p value < 0.00001) with CRP
phenotype in the CHS (Table 4), including two common,
nonsynonymous coding SNPs, rs1169288 (Ile27Leu) and
rs2464196 (Ser486Asn). The strongest association was
with rs1169310, which is located in the HNF1A 30 untrans-
lated region [log10(BF) ¼ þ8.6]. When adjusted for age,
sex, clinic, body-mass index, and smoking status, each ad-
ditional copy of the rs1169310 minor allele was associated
with 0.13 (0.08 – 0.17) mg/l lower mean log(CRP) levels.
Haplotype analysis of the eight HNF1A tagSNPs typed in
the CHS showed that the minor alleles of rs1169288,
rs1169286, rs2464196, and rs1169310 constitute a com-
mon haplotype (frequency 30%) associated with lower
CRP levels (Table 5).Table 2. SNPs with Strongest Evidence of Association with C-Reactive Protein in the PARC Combined Stage 1 and Stage 2
Genome-Wide Association Study
rs Number Chr. Position Gene
Number with Nonmissing
Genotype and CRP Phenotype
Log10 Bayes
Factor p Value(Permutation)
rs2794520 1 157945440 CRP 1682 6.6 < 1 3 107
rs2075650 19 50087459 APOE 1678 5.7 < 1 3 107
rs2592887 1 157919563 CRP 1680 4.8 < 1 3 107
rs6481464 10 60790490 FAM13C1 1682 3.9 2 3 106
rs7953249 12 119888107 HNF1A 1681 3.5 4 3 106
rs735396 12 119923227 HNF1A 1682 3.3 5 3 106
rs12093699 1 157914612 CRP 1682 3.3 7 3 106
rs11265260 1 157966663 CRP 1682 3.3 7 3 106
rs7730843 5 36578069 SLC1A3 1679 3.2 1.5 3 105y 2008
We used the imputation-based method of Servin and
Stephens7 to combine typed SNP-genotype and CRP-phe-
notype data from the PARC study and the CHS with infor-
mation on multimarker linkage disequilibrium (LD) from
the HapMap and hence to assess the strength of evidence
Figure 1. Distribution of Bayes Factors
Associated with C-Reactive Protein in
Stage 1 of PARC Genome-wide Associa-
tion Study
A quantile-quantile plot comparing the
distribution of log10(Bayes Factor) in the
PARC study with the distribution under
the null (generated by computation of
the log10[Bayes Factor] for all SNPs for
five random phenotype vectors, each ob-
tained by randomly permutation of the
original phenotypes across individuals).
The red line indicates a straight line
through the origin with unit slope. The
color purple indicates the points that
relate to the SNPs in Table 2.
Table 3. Global Bayes Factors for Candidate Genes Showing Strongest Evidence of Association with C-Reactive Protein in CHS
Gene Gene # Chr. Position
# SNPs
Typed Description
Log10 Bayes
Factor
p Value
(Permutation)
CRP 1401 1 157,948,704–157,951,003 4 C-reactive protein 24.8 < 1 3 106
APOE 348 19 50,100,879–50,104,489 2 Apolipoprotein E 9.9 < 1 3 106
HNF1A 6927 12 119,900,932–119,924,695 8 Transcription factor 1; hepatic nuclear
factor (HNF)-1a
7.7 < 1 3 106
PARP1 142 1 224,615,129–224,662,414 9 Poly (ADP-ribose) polymerase family, member 1 0.7 0.012
CEBPD 1052 8 48,812,029–48,813,279 1 CCAAT/enhancer binding protein delta 0.7 0.016
ATF3 467 1 210,848,617–210,860,737 15 Activating transcription factor 3 0.5 0.012
GP6 51206 19 60,216,887–60,241,444 8 glycoprotein VI (platelet) 0.4 0.017
CPB2 1361 13 45,525,323–45,577,212 11 Carboxypeptidase B2 0.3 0.016
SP1 6667 12 52,060,246–52,096,493 5 Sp1 transcription factor 0.3 0.039
IL6 3569 7 22,732,028–22,738,091 7 Interleukin-6 0.3 0.021
TIRAP 114609 11 125,658,192–125,670,038 8 Toll-interleukin 1 receptor (TIR)
domain containing adaptor protein
0.2 0.048
F7 2155 13 112,808,106–112,822,995 5 Coagulation factor VII 0.2 0.046
IL1RN 3557 2 113,591,941–113,608,063 11 Interleukin-1 receptor antagonist 0.2 0.045
F2 2147 11 46,697,331–46,717,631 7 Coagulation factor II precursor 0.2 0.042
PROZ 8858 13 112,860,969–112,874,695 31 protein Z, vitamin K-dependent plasma glycoprotein 0.1 0.034
HMOX1 3162 22 34,107,087–34,120,194 8 heme oxygenase (decycling) 1 0.1 0.034
PNPT1 87178 2 55,715,971–55,774,463 9 Polyribonucleotide nucleotidyltransferase 1 0.02 0.042
Global Bayes Factors test the null hypothesis of no association between any SNP in the candidate-gene region versus the alternative that one SNP is
associated, and are given by the average of the single-SNP Bayes Factors in the region7.
for phenotypic association with
typed and untyped SNPs located
within the chromosome 12 HNF1A
region. Of 193 known SNPs encom-
passing a ~200 kb region ﬂanking
the HNF1A gene, the strongest evi-
dence for CRP phenotype association
in the combined PARC þ CHS sample
consisted of a cluster of ﬁve ‘‘un-
typed’’ SNPs in perfect LD with one another (rs7310409,
rs2393775, rs7979473, rs2393791, and rs7979478) located
within a 5 kb region spanning the 30 half of theHNF1A ﬁrst
intron (Figure 2 and Table 6). With the assumption that
a single SNP is responsible for the observed associationThe American Journal of Human Genetics 82, 1193–1201, May 2008 1195
Table 4. HNF1A SNPs Typed in CHS and their Associations with Plasma Log(CRP) Concentration
rs #
Chr. 12
Coordinate Location Alleles
Minor-Allele
Frequency
Number with
Nonmissing Genotype
and CRP Phenotype
Regression
Coefficient
(95% CI)
Single-SNP
Bayes Factor
Log(10)
Nominal
p Value
rs1169288 119901033 Exon 1
(Ile27Leu)
A/C 0.28 4328 0.12 (0.07 to 0.16) þ6.0 2.6 3 107
rs1169286 119903439 Intron 1 T/C 0.36 4332 0.10 (0.06 to 0.15) þ4.8 1.6 3 106
rs1169293 119910928 Intron 1 A/G 0.11 4332 0.11 (0.03 to 0.19) þ0.9 0.008
rs12427353 119911284 Intron 2 G/C 0.17 4333 þ0.09 (0.04 to 0.14) þ1.7 0.001
rs2071190 119915655 Intron 2 T/A 0.23 4333 þ0.04 (0.01 to 0.09) þ1.0 0.16
rs2464196 119919810 Exon 7
(Ser486Asn)
G/A 0.28 4329 0.11 (0.06 to 0.16) þ6.3 1.9 3 106
rs1169303 119920759 Intron 7 A/C 0.47 4330 0.11 (0.06 to 0.15) þ4.9 9.7 3 107
rs1169310 119923816 30 UTR G/A 0.38 4330 0.13 (0.08 to 0.17) þ8.6 1.7 3 108
Estimates, 95%CI, and p-values were derived from single-SNP multiple linear regression models.
Regression coefficients estimate the increase/decrease in log(CRP) level per each additional copy of the minor allele, adjusted for age, sex, clinic, body
mass index, and smoking.with plasma CRP levels, our analyses estimated> 99% pos-
terior probability that the SNP is one of these ﬁve HNF1A
intron 1 SNPs. However, there was considerable uncer-
tainty about exactly which SNP is most likely to be respon-
sible for the association, with all ﬁve single-SNP log10(BF)s
in the range of þ16.0 to þ16.2. It is also possible that
a non-HapMap SNP, in LD with these ﬁve SNPs, is respon-
sible for the association. Sensitivity analyses involving
HNF1A genotype imputation and regression performed
separately in the PARC study and the CHS showed similar
results (Table 6). The estimated pairwise LDs between each
of the ﬁve intron 1 SNPs and the two nonsynonymous
SNPs typed in the CHS were r2 ¼ 0.62 for rs1169288
(Ile27Leu) and r2 ¼ 0.54 for rs2464196 (Ser486Asn).
CRP is produced primarily by hepatocytes, and its syn-
thesis is largely under transcriptional control of various cy-
tokines (interleukin [IL]-6 and IL-1b) and transcription-fac-
tor complexes, including CAAT enhancer binding protein
and NF-kB.15 An HNF-1a binding site in the CRP gene pro-
moter overlaps with a binding site for NFkB and is involved
in the regulation of basal and constitutive CRP synthesis in
the liver.16,17 Our combined evidence from two genetic-
association studies shows that the HNF1A gene encoding
HNF-1a is associated with plasma CRP concentration. Ad-
ditional conﬁrmatory evidence of the association between
the HNF1A genotype and the CRP phenotype in a GWA
analysis of over 6000 participants from the Women’s1196 The American Journal of Human Genetics 82, 1193–1201, MayGenomeHealth Study (WGHS) is provided in the accompa-
nying article by Ridker et al.18 Notably, one of the ﬁve in-
tron 1 ‘untyped’ SNPs identiﬁed as the strongest candidates
for CRP phenotype association in the combined PARC and
CHS analysis (rs7310409) was the typed HNF1A SNP most
strongly associated with CRP inWGHS.18 This observation
emphasizes the utility of imputation-based methods for
the combination and comparing of results across studies
that have typed different SNPs.
In addition to HNF1A, CRP, and APOE, three other genes
(LEPR [MIM 601007], IL6R [MIM 147880], andGCKR [MIM
600842]) were reported to be associated with CRP in the
accompanying article by Ridker et al. In our PARC GWA
study, the log10(BF) for rs1260326 in GCKR was þ1.3
(p ¼ 0.005). The same GCKR SNP (rs1260326) or other
GCKR SNPs in strong LD have been associated with serum
triglycerides in recent GWA data from several groups,19
including PARC (R.M.K., personal communication). GCKR
encodes a hepatic and pancreatic glucokinase regulatory
protein, which regulates glucokinase (GCK [MIM
138079]), a susceptibility gene for maturity-onset diabetes
of the young (MODY [MIM 606391]).20 Interestingly, rare
mutations in HNF1A are also associated with MODY,21
and the HNF1A gene product HNF-1a is an important tran-
scriptional regulator of a number of hepatic and pancreatic
islet cell genes.Together, theseobservations suggest thepos-
sibility that CRP and metabolic phenotypes might, at leastTable 5. HNF1A Haplotypes Estimated from Eight TagSNPs and their Associations with Plasma Log(CRP) Concentration in CHS
HNF1A Haplotype rs1169288 rs1169286 rs1169293 rs12427353 rs2071190 rs2464196 rs1169303 rs1169310 Frequency
Score
Statistic
p
Value
Haplotype 1 2 2 1 1 1 2 2 2 0.30 6.11 < 1 3 105
Haplotype 2 1 1 1 2 1 1 1 1 0.19 3.66 0.003
Haplotype 3 1 1 1 1 1 1 1 1 0.15 2.24 0.03
Haplotype 4 1 1 1 1 2 1 2 1 0.11 1.85 0.06
Haplotype 5 1 2 1 1 2 1 1 1 0.10 1.99 0.05
Haplotype 6 1 1 2 1 1 1 2 2 0.06 2.26 0.02
Presence of the major or minor allele at each SNP is indicated by the numbers 1 and 2, respectively. Only haplotypes having an estimated frequency of> 5%
were included in the analysis. The global score statistic for the overall association of HNF1A haplotypes and CRP was 52.6 (p value ¼ 1 3 109).2008
in part, be under coordinate genetic control. It is unclear
whether our failure to ﬁnd a strong genome-wide signal
forCRPassociation atLEPRor IL6R in PARC (Table 7) reﬂects
our smaller sample size or a genuine difference between the
Figure 2. Strength of Evidence for
Association between HNF1A SNP and CRP
Phenotype in PARC and CHS Combined
The vertical lines represent log10(Bayes
Factors) (y axis) for each SNP in a ~200
kilobase region encompassing the HNF1A
gene on chromosome 12. SNPs are num-
bered according to chromosomal position
on the x axis. The color of the vertical
line indicates whether the SNP was directly
observed in PARC (green), directly ob-
served in CHS (red), directly observed in
both PARC and CHS (pink), or indirectly ob-
served by imputation from the HapMap
(black). The gray shaded region demar-
cates the 50 and 30 boundaries of the
HNF1A gene. Highlighted in yellow is
the 5 kilobase region containing the five
intron-1 SNPs showing the strongest
evidence of association with CRP.
Table 6. Bayesian Imputation-Based Association Analysis of HNF1A SNPs and Log(CRP) Concentration: Results from PARC, CHS,
and Both Studies Combined
PARC CHS CHS þ PARC Combined
rs #
Chr. 12
coordinate Location
SNP Typed in PARC
or CHS
Single-
SNP BF
Log(10) p Value
Single-
SNP BF
Log(10) p Value
Single-
SNP BF
Log(10) p Value
rs7979473 119904643 Intron 1 þ4.1 < 1 3 106 þ11.1 < 1 3 106 þ16.2 < 1 3 106
rs7979478 119904646 Intron 1 þ4.1 < 1 3 106 þ11.1 < 1 3 106 þ16.2 < 1 3 106
rs2393791 119908339 Intron 1 þ4.1 < 1 3 106 þ11.0 < 1 3 106 þ16.1 < 1 3 106
rs7310409 119909244 Intron 1 þ4.1 < 1 3 106 þ11.0 < 1 3 106 þ16.1 < 1 3 106
rs2393775 119908957 Intron 1 þ4.0 < 1 3 106 þ11.0 < 1 3 106 þ16.0 < 1 3 106
rs10774579 119889593 50 flank þ4.4 < 1 3 106 þ7.8 < 1 3 106 þ14.7 < 1 3 106
rs7305618 119887315 50 flank þ3.2 < 1 3 106 þ6.4 < 1 3 106 þ14.0 < 1 3 106
rs7953249 119888107 50 flank PARC þ3.6 < 1 3 106 þ9.3 < 1 3 106 þ13.7 < 1 3 106
rs2464195 119919858 Intron 7 þ3.3 < 1 3 106 þ8.6 < 1 3 106 þ13.3 < 1 3 106
rs1169306 119922694 Intron 9 þ3.1 < 1 3 106 þ8.3 < 1 3 106 þ13.2 < 1 3 106
rs2259816 119919970 Intron 7 þ3.3 < 1 3 106 þ8.6 < 1 3 106 þ13.0 < 1 3 106
rs1169312 119925844 30 UTR þ3.5 < 1 3 106 þ8.5 < 1 3 106 þ13.0 < 1 3 106
rs1169310 119923816 30 UTR CHS þ3.3 < 1 3 106 þ8.6 < 1 3 106 þ12.9 < 1 3 106
rs735396 119923227 Intron 9 PARC þ3.3 < 1 3 106 þ8.5 < 1 3 106 þ12.8 < 1 3 106
rs1169313 119927053 30 flank þ3.4 < 1 3 106 þ8.3 < 1 3 106 þ12.7 < 1 3 106
rs1182933 119939005 30 flank þ3.2 < 1 3 106 þ7.5 < 1 3 106 þ11.5 < 1 3 106
rs11065385 119907769 Intron 1 þ3.5 < 1 3 106 þ7.4 < 1 3 106 þ11.5 < 1 3 106
rs1183910 119905190 Intron 1 þ3.5 < 1 3 106 þ7.5 < 1 3 106 þ11.5 < 1 3 106
rs2649999 119864927 50 flank þ2.8 < 1 3 106 þ6.5 < 1 3 106 þ11.3 < 1 3 106
rs2244608 119901371 Intron 1 þ3.2 < 1 3 106 þ6.8 < 1 3 106 þ10.9 < 1 3 106
Global test – – þ2.9 2 3 105 þ9.4 < 1 3 106 þ14.5 < 1 3 106
PARC results and the WGHS results.
Nonetheless, there is prior evidence
linking leptin and the leptin receptor
to CRP.22
In summary, we report an associa-
tion between common variants of
theHNF1A gene encodingHNF-1a andplasmaCRPconcen-
tration in two independent populations of older adults.
Given the association between plasma CRP concentration
and various metabolic and cardiovascular diseases, largerThe American Journal of Human Genetics 82, 1193–1201, May 2008 1197
Table 7. Evidence for Association between CRP and LEPR, IL6R, and GCKR SNPs Typed in PARC Genome-wide Association Study
Gene SNP Chr. Position
Number with
Nonmissing Genotype
and CRP Phenotype
Log10
Bayes Factor p Value
LEPR rs1892534 1 65878532 909 0.16 0.24
rs2889195 1 65929318 909 0.26 0.35
rs2211651 1 65928609 908 0.22 0.31
rs12753193 1 65942267 909 0.22 0.26
rs2186245 1 65890652 909 0.35 0.76
rs12022410 1 65926521 909 0.02 0.12
rs7539471 1 65957991 909 0.18 0.23
rs4291477 1 65963663 909 þ0.12 0.06
rs4655537 1 65831389 908 þ0.24 0.05
IL6R rs4129267 1 152692888 909 þ0.26 0.04
GCKR rs780094 2 27594741 909 þ0.16 0.06
rs1260326 2 27584444 1678 þ1.3 0.005
rs1260333 2 27602128 906 0.20 0.27studies assessing the potential association of HNF1A geno-
type withmore complex, clinical-disease-related endpoints
could shed additional light on the role of genetic regulation
of CRP on the occurrence of disorders such as myocardial
infarction, stroke, diabetes, and metabolic syndrome.23,24
Appendix
CRP Phenotype
Multiple CRP measurements were available for the major-
ity of participants in both the PARC (pre- and post-statin
treatment) study and the CHS (baseline and after three
years of follow up). For reduction of the effects of measure-
ment error and environmental variation on the CRP
phenotype, all available values for plasma CRP of each
participant were combined into a single value, as follows.
In theCHS, a normal quantile transformation of CRPwas
ﬁrst performed at each time point to improve the normality
of model residuals. To reduce effects of environmental
inﬂuences, we adjusted quantile-transformed CRP levels
for strong predictors (age, sex, clinic, smoking, body-mass
index) at each time point by using multiple linear regres-
sion and taking the standardized residuals. Covariate-
adjusted normalized CRP residuals were then averaged
across time points when multiple measures were available
for a given participant, and a single valuewas used for those
subjects with only one measure. The ﬁnal averaged values
were again quantile normalized to have mean of 0 and
variance of 1 prior to analysis.
In PARC, the phenotypes were processed separately
in the two studies (CAP and PRINCE), following the same
procedure as that in the CHS except that the quantile-
transformed CRP phenotypes were ﬁrst averaged across
time points and then covariate-corrected (for age, sex,
smoking, body-mass index), rather than the covariate cor-
rection being performed within each time point. Separate
processing of the phenotype in each study avoids potential
spurious associations due to systematic differences (e.g., in
population structure) between the two studies. Note that1198 The American Journal of Human Genetics 82, 1193–1201, Maphenotype averaging across time points in PARC includes
values from both pre- and post- statin exposure. Because
statin exposure affects CRP levels variably across individ-
uals, the post-statin measurements in PARC might be
considered ‘‘noisy’’ measures of the baseline CRP. However,
the noise levels are low (intra-individual correlation of pre-
and post-statin CRP ¼ 0.75). In addition, the Bayes Factors
for previously reported associations of CRP phenotype
with SNPs in APOE and CRP genes were larger (by up to
a factor of 10) for the averaged phenotype than for baseline
phenotype only, suggesting that measurement error is re-
duced, and true genetic signals enhanced, by the averaging
of pre- and post-statin values. These results emphasize the
potential utility of the averaging of multiple measures of
phenotypes over time.
Adjustment for Population Stratiﬁcation
To examine the potential effects of within-Europe popula-
tion stratiﬁcation in PARC, we also analyzed phenotypes
for individuals in stage 1 after correction for population
stratiﬁcation with principal-components analysis.9 Specif-
ically, we computed the ﬁrst ten principal components
from the 317,000 SNPs typed in stage 1 individuals, mask-
ing regions of the genome known to harbor inversions,
or unusual patterns of LD, which can give rise to PCs unre-
lated to population structure.8 We also excluded SNPs
on the basis of pairwise genotypic correlation, removing
SNPs from pairs with r2 > 0.2 in sliding windows of
500 SNPs, while shifting the window in increments of
ﬁve SNPs at each step. Three of these PCs (1, 2, and 5)
were correlated with CRP phenotypes (Spearman rank-cor-
relation p value < 0.05), so we adjusted the phenotype by
taking the residuals obtained from multiple linear regres-
sion of the phenotype on these PCs.
Genotyping Methods and Quality Control
In PARC, study participants were randomly divided into
discovery (stage 1) and conﬁrmation (stage 2) sets. A total
of 980 PARC subjects (305 CAP participants þ 675 PRINCE
participants) were typed in stage 1 for a panel of 317,000y 2008
tagSNPs derived from phase IþII of the International
HapMap Project. Genomic linkage disequilibrium cover-
age in Caucasians for all Phase IþII loci is 91% for an r2
threshold% 0.5 and 80% for an r2 threshold% 0.8. Geno-
typing was performed at the University of Washington,
Department of Genome Sciences using the Illumina Inﬁn-
ium technology on an automated Iluumina BeadStation
system with the Sentrix(R) Human-1 BeadChip (Illumina
Inc. San Diego CA). Analysis of blind duplicate quality con-
trol samples using ~18,000 SNPs contained on the 317K
GWA chip and a separate 109K GWA chip showed a geno-
typing concordance rate of 99.97%. In PARC stage 2, an ad-
ditional 930 PARC subjects (294 CAP participants þ 636
PRINCE participants) were typed for a total of 13,680
SNPs selected on the basis of the results of a broader
GWA survey within the PARC study of SNPs and haplo-
types showing statistical evidence of association with a va-
riety of lipid-related phenotypes or CRP phenotype in
Stage 1, as well as to providemore detailed tagSNP coverage
for additional candidate genes within pathways related to
lipid metabolism. The PARC stage 2 custom genotyping
panel contained 3 SNPs (rs868795, rs7953249, rs735396)
located within the ~200kb region encompassing HNF1A.
The stage 2 SNPs were typed using the Illumina iSelect sys-
tem (Illumina Inc. San Diego CA).The genotyping of the
custom panel in PARC stage 2 showed call rates of >
99.85% with only 193 (1.48%) of the 12,959 sites failing
to work. The replicate error rate for six samples run in
duplicate was 0.002%.
In the CHS, genomic sequence variation data were avail-
able for many of our candidate genes through the Na-
tional Heart, Lung, and Blood Institute-funded Seat-
tleSNPs Program for Genomics Applications (PGA). For
genes not re-sequenced by the PGA, we used genotype
data available from the International HapMap project. Us-
ing the LDselect algorithm of Carlson et al.,25 we selected
a set of tagSNPs that capture common patterns of genetic
variation within our genes of interest. Genotyping for the
majority of our candidate genes was performed using the
Illumina GoldenGate platform by the Center for Inherited
Disease Research, Johns Hopkins University (Baltimore,
Maryland, USA). TagSNPs from 20 additional candidate
genes were typed at the Laboratory for Clinical Biochem-
istry Research (University Vermont) with the ABI TaqMan
platform using Assays By Design on an ABI 7900 real time
thermal cycler under standard conditions (TaqMan SNP
Genotyping Assays Protocol, Rev. B, Part #4332856b, Ap-
plied Biosystems, Foster City, CA). After removing SNPs
with minor allele frequency < 5% and those with missing
rates> 25%, there were 979 SNPs for analysis. For both the
Illumina and TaqMan platforms, overall genotype missing
rate was < 0.1%; genotyping failure rate did not exceed
4.2% for any of the SNPs under study. Concordance rates
for blind duplicate samples was > 99.5% for all SNPs as-
says across both genotyping platforms. After removing
195 individuals with > 25% missing genotypes, the total
genotyping rate in the remaining individuals was > 99%.The AmBayesian Regression and Imputation Analysis
To assess the strength of evidence for association between
candidate genes or individual SNPs and CRP, we used the
‘‘Bayesian IMputation-BasedAssociationMapping’’method
of Servin and Stephens implemented in the program
BIMBAM.7 BIMBAM quantiﬁes the strength of evidence
for association by computing Bayes Factors (BFs) for each
SNP. The quantile normalized mean covariate-adjusted
CRP values were used as the quantitative phenotype for
the BIMBAM analysis. BFs were computed under the linear
model
Yi ¼ mþ aXi þ dIðXi ¼ 1Þ þ 3i
where Yi denotes the CRP phenotype for individual i,Xi de-
notes the genotype for individual i (coded as 0, 1 or 2), a de-
notes the additive effect, d denotes the dominance effect,
and 3i denotes an error term. The BFs were computed using
the prior D2,7 averaging over sa ¼ 0.05, 0.1, 0.2, 0.4 and
sd ¼ sa/4. In the PARC analysis we computed a single-SNP
BF for each of the 317,000 genotyped SNPs, and single-SNP
p values were obtained from these BFs by permutation.7
In the CHS analysis, we used BIMBAM to compute a global
BF for each gene, as the average of the single-SNP BFs across
SNPs in each gene, and obtained corresponding p values
(for the global null that none of the SNPs in the gene are
associated with phenotype) by permutation, which ac-
counts for correlation among SNPs in the same gene due
to linkage disequilibrium.7 Each permutation test involved
100,000 to 10,000,000 permutations, depending on the
level of signiﬁcance attained.
Imputation-based methods such as BIMBAM are particu-
larly useful for combining data from multiple studies that
have typed different SNPs in the same candidate region us-
ing different genotyping platforms. Patterns of correlation
or LD among the markers typed in each phenotypic data
set (CHS, PARC discovery set, PARC conﬁrmation set)
and a more densely-genotyped genotype panel (HapMap
CEU parents) were used to impute the genotypes at all
HapMap markers in and near HNF1A, in all individuals,
allowing the combined data to be used when assessing
the strength of the association between genotypes and
the phenotype.7 In the combined imputation analysis,
we computed single-SNP BF and permutation p-values for
each untyped SNP using the posterior mean genotype as
the estimated genotype. This single-imputation method,
ignoring uncertainty in imputed genotypes, gives similar
results to averaging over multiple imputations (Y. Guan
and M. Stephens, unpublished data). Posterior probabili-
ties for each SNP being responsible for an observed associ-
ation, conditional on exactly one SNP in the region being
responsible, were obtained from the single-SNP BFs by nor-
malizing them to sum to 1 (implicitly assuming that each
SNP is equally likely, a priori, to be responsible).
To estimate effect sizes of individual SNP genotypes on
CRP phenotype in the CHS, we performed multiple linear
regression models, using log-transformed CRP as the de-
pendent variable and assuming a constant effect size forerican Journal of Human Genetics 82, 1193–1201, May 2008 1199
eachadditional copyof theminor allele.Covariate-adjusted
SNP-speciﬁc change in estimated mean plasma log(CRP)
levelwas estimated fromthe regressioncoefﬁcient (b). Anal-
ysis of the associationbetweenHNF1Ahaplotypes andbase-
line log-transformedCRP levels in theCHSparticipants, ad-
justed for covariates (age, sex, clinic, body mass index,
smoking) was performed using the haplotype estimation
andgeneralized linearmodel score test framework of Schaid
et al.,26 implemented in the statistical package Haplo.stats.
To assess the robustness of our results of the association
between the HNF1A genotype and the CRP phenotype, we
performed several additional sensitivity analyses. Analyses
restricted to subjects with CRP levels < 10 mg/l produced
results similar to those using all subjects. Additional adjust-
ment for, or exclusion of, the small number of hormone
therapy replacement users from the CHS similarly did
not have an appreciable impact on any of our results.
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